Zhao Hai, Bo Cong, Kang Yan, Li Hong
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Obstetrics & Gynecology, Pediatric Diseases, and Birth Defects of the Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China.
Front Immunol. 2017 Jun 22;8:727. doi: 10.3389/fimmu.2017.00727. eCollection 2017.
As the rate-limiting enzyme in ATP/ADP-AMP-adenosine pathway, CD39 would be a novel checkpoint inhibitor target in preventing adenosine-triggered immune-suppressive effect. In addition, CD39 Tregs, but not CD25 Tregs, exhibit sustained Foxp3 levels and functional abilities, indicating it could represent a new specific marker of Tregs. Similarly, inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Far from conclusive, present research revealed that CD39 also dephosphorylated and thus inactivated self- and pathogen-associated phosphoantigens of Vγ9Vδ2 T cells, which may be the most promising subpopulation for cellular vaccine. CD39 is also tightly related to Th17 cells and can be regarded as a Th17 cells marker. In this review, we focus on present research of CD39 ectoenzyme and provide insights into its clinical application.
作为ATP/ADP-AMP-腺苷途径中的限速酶，CD39可能是预防腺苷触发的免疫抑制效应的新型检查点抑制剂靶点。此外，CD39调节性T细胞而非CD25调节性T细胞表现出持续的Foxp3水平和功能能力，这表明它可能代表调节性T细胞的一种新的特异性标志物。同样，抑制肿瘤细胞表面的CD39酶功能可减轻其免疫抑制活性。目前的研究远未得出定论，研究表明CD39还可使Vγ9Vδ2 T细胞的自身及病原体相关磷酸抗原去磷酸化并使其失活，而Vγ9Vδ2 T细胞可能是细胞疫苗最有前景的亚群。CD39也与Th17细胞密切相关，可被视为Th17细胞标志物。在本综述中，我们聚焦于CD39胞外酶的当前研究，并对其临床应用提出见解。
